MA30967B1 - Sels et formes cristallines de 2-methyl-2-methyl-2-[4-(3-methyl-2-oxo-8-quinolein-3-yl-2,3-dihydro-imidazo[4,5-c]quinolein-1-yl) - phenyl]-propionitrile. - Google Patents

Sels et formes cristallines de 2-methyl-2-methyl-2-[4-(3-methyl-2-oxo-8-quinolein-3-yl-2,3-dihydro-imidazo[4,5-c]quinolein-1-yl) - phenyl]-propionitrile.

Info

Publication number
MA30967B1
MA30967B1 MA31947A MA31947A MA30967B1 MA 30967 B1 MA30967 B1 MA 30967B1 MA 31947 A MA31947 A MA 31947A MA 31947 A MA31947 A MA 31947A MA 30967 B1 MA30967 B1 MA 30967B1
Authority
MA
Morocco
Prior art keywords
methyl
propionitrile
imidazo
quinoline
dihydro
Prior art date
Application number
MA31947A
Other languages
English (en)
Inventor
Frank Stowasser
Markus Baenziger
Sudhakar Devidasrao Garad
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39345299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30967(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30967B1 publication Critical patent/MA30967B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'INVENTION CONCERNE DES FORMES CRISTALLINES PARTICULIÈRES DE 2-MÉTHYL-2-[4-(3-MÉTHYL-2-OXO-8-QUINOLÉIN-3-YL-2,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLÉIN-1-YL)- PHÉNYL]-PROPIONITRILE, LEURS HYDRATES ET SOLVATES, LEURS SELS ET HYDRATES ET SOLVATES DE SES SELS, CERTAINS PROCÉDÉS POUR LEUR PRÉPARATION, LES COMPOSITIONS PHARMACEUTIQUES CONTENANT CES FORMES CRISTALLINES, ET LEUR UTILISATION DANS DES PROCÉDÉS DIAGNOSTIQUES OU, DE PRÉFÉRENCE, POUR LE TRAITEMENT THÉRAPEUTIQUE D'ANIMAUX À SANG CHAUD, SPÉCIALEMENT DES ÊTRES HUMAINS, ET LEUR UTILISATION COMME INTERMÉDIAIRE OU POUR LA PRÉPARATION DE PRÉPARATIONS PHARMACEUTIQUES POUR UNE UTILISATION DANS DES PROCÉDÉS DIAGNOSTIQUES OU, DE PRÉFÉRENCE, POUR LE TRAITEMENT THÉRAPEUTIQUE D'ANIMAUX À SANG CHAUD, SPÉCIALEMENT DES ÊTRES HUMAINS.
MA31947A 2006-11-20 2009-06-03 Sels et formes cristallines de 2-methyl-2-methyl-2-[4-(3-methyl-2-oxo-8-quinolein-3-yl-2,3-dihydro-imidazo[4,5-c]quinolein-1-yl) - phenyl]-propionitrile. MA30967B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86648306P 2006-11-20 2006-11-20

Publications (1)

Publication Number Publication Date
MA30967B1 true MA30967B1 (fr) 2009-12-01

Family

ID=39345299

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31947A MA30967B1 (fr) 2006-11-20 2009-06-03 Sels et formes cristallines de 2-methyl-2-methyl-2-[4-(3-methyl-2-oxo-8-quinolein-3-yl-2,3-dihydro-imidazo[4,5-c]quinolein-1-yl) - phenyl]-propionitrile.

Country Status (35)

Country Link
US (2) US8436177B2 (fr)
EP (2) EP2094700B1 (fr)
JP (2) JP5562033B2 (fr)
KR (3) KR20140129396A (fr)
CN (5) CN102336752A (fr)
AR (1) AR064256A1 (fr)
AU (1) AU2007323820B2 (fr)
BR (1) BRPI0719112A2 (fr)
CA (1) CA2669199C (fr)
CL (1) CL2007003316A1 (fr)
CO (1) CO6382134A2 (fr)
CR (1) CR10757A (fr)
DO (1) DOP2009000116A (fr)
EA (1) EA015677B1 (fr)
EC (1) ECSP099340A (fr)
GE (1) GEP20125436B (fr)
GT (1) GT200900133A (fr)
HR (1) HRP20140627T1 (fr)
IL (2) IL198467A (fr)
JO (1) JO2903B1 (fr)
MA (1) MA30967B1 (fr)
MX (1) MX2009005360A (fr)
MY (1) MY150216A (fr)
NI (1) NI200900091A (fr)
NO (1) NO20092227L (fr)
NZ (1) NZ576357A (fr)
PE (2) PE20081780A1 (fr)
PH (1) PH12013502100A1 (fr)
RS (1) RS53335B (fr)
SM (1) SMP200900041B (fr)
TN (1) TN2009000191A1 (fr)
TW (2) TWI417292B (fr)
UA (1) UA98473C2 (fr)
UY (1) UY30728A1 (fr)
WO (1) WO2008064093A2 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
AU2009204483B2 (en) 2008-01-04 2014-03-13 Intellikine, Llc Certain chemical entities, compositions and methods
JP5519627B2 (ja) * 2008-03-26 2014-06-11 ノバルティス アーゲー Ｖｅｇｆ促進性血管新生過程の強力なモジュレーターとしての５イミダゾキノリン誘導体およびピリミジン誘導体
WO2010036380A1 (fr) 2008-09-26 2010-04-01 Intellikine, Inc. Inhibiteurs hétérocycliques de kinases
WO2010129816A2 (fr) 2009-05-07 2010-11-11 Intellikine, Inc. Composés hétérocycliques et leurs utilisations
CN102574845B (zh) 2009-06-04 2015-09-02 诺华股份有限公司 1H-咪唑并[4,5-c]喹啉酮衍生物
PH12012501581A1 (en) 2010-02-03 2012-10-22 Signal Pharm Llc Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
DE102010035744A1 (de) * 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20180080358A (ko) 2011-01-10 2018-07-11 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀린온 및 이의 고체 형태의 제조 방법
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
EP2734530A1 (fr) 2011-07-19 2014-05-28 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
IN2014CN02315A (fr) * 2011-09-30 2015-06-19 Dana Farber Cancer Inst Inc
US9499561B2 (en) 2012-04-10 2016-11-22 Shanghai Yingli Pharmaceutical Co., Ltd. Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
IL291945B2 (en) 2012-11-01 2025-11-01 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CN112641787A (zh) 2013-03-21 2021-04-13 诺华股份有限公司 包含B-Raf抑制剂和第二抑制剂的组合疗法
JP6382945B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
BR112015026257B1 (pt) 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
MX368286B (es) 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
EP2986321A1 (fr) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Polythérapie comprenant un inhibiteur de la kinase tor et un analogue de la cytidine pour le traitement du cancer
CN105339008A (zh) 2013-04-17 2016-02-17 西格诺药品有限公司 用于治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯酰胺的组合疗法
MX393164B (es) 2013-04-17 2025-03-21 Signal Pharm Llc Formulaciones farmacéuticas, proceso, formas sólidas y métodos de uso relacionados con 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-ii)piridin-3-ii)-3,4-dihidropirazino[2,3-b]pirazin-2(1h)-ona.
HK1221150A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用二氢吡嗪并-吡嗪类对癌症的治疗
NZ629486A (en) 2013-05-29 2017-11-24 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
WO2015043398A1 (fr) 2013-09-30 2015-04-02 上海璎黎药业有限公司 Composé de pyrimidine condensée, intermédiaire, procédé de préparation s'y rapportant et composition et application correspondantes
WO2015051241A1 (fr) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
CA2926596C (fr) 2013-10-16 2020-07-14 Shanghai Yingli Pharmaceutical Co., Ltd Compose heterocyclique condense, son procede de preparation, composition pharmaceutique et leurs utilisations
EP4066834A1 (fr) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Composés hétérocycliques pour une utilisation dans le traitement de troubles à médiation pi3k-gamma
EP3131551A4 (fr) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC Formes solides comprenant 1-éthyl-7-(2-méthyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1h)-one, et co-formateur, compositions et procédés d'utilisation de ces dernières
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2016054491A1 (fr) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
WO2016185443A1 (fr) 2015-05-20 2016-11-24 Novartis Ag Combinaison pharmaceutique d'évérolimus et de dactolisib
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (fr) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
CA3028718A1 (fr) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Polytherapies
WO2018096402A1 (fr) 2016-11-23 2018-05-31 Novartis Ag Méthodes d'amélioration de la réponse immunitaire à l'évérolimus, au dactolisib ou aux deux
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
WO2019157516A1 (fr) 2018-02-12 2019-08-15 resTORbio, Inc. Polythérapies
CN111187181B (zh) * 2019-11-22 2023-05-05 吉林大学 一种2-(4-氨基苯基)-2-甲基丙腈化合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
AR046845A1 (es) * 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
PT1687305E (pt) * 2003-11-21 2008-10-17 Novartis Ag Derivados de 1h-imidazoquinolina como inibidores de proteína quinase
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
TN2009000191A1 (en) 2010-10-18
PH12013502100A1 (en) 2015-09-21
EP2364981A1 (fr) 2011-09-14
KR20140129396A (ko) 2014-11-06
CN101541793A (zh) 2009-09-23
TW201402567A (zh) 2014-01-16
AU2007323820A1 (en) 2008-05-29
SMP200900041B (it) 2009-09-07
HK1132739A1 (en) 2010-03-05
KR20090080530A (ko) 2009-07-24
IL219877A0 (en) 2012-06-28
TWI417292B (zh) 2013-12-01
CN106045993A (zh) 2016-10-26
RS53335B (sr) 2014-10-31
NO20092227L (no) 2009-08-17
MY150216A (en) 2013-12-13
NI200900091A (es) 2010-02-17
US8436177B2 (en) 2013-05-07
EA015677B1 (ru) 2011-10-31
CL2007003316A1 (es) 2008-06-27
PE20081780A1 (es) 2009-01-01
CN102993202A (zh) 2013-03-27
UA98473C2 (ru) 2012-05-25
BRPI0719112A2 (pt) 2013-12-10
EP2094700B1 (fr) 2014-04-02
TW200827356A (en) 2008-07-01
DOP2009000116A (es) 2009-05-31
CA2669199C (fr) 2015-12-29
EP2094700A2 (fr) 2009-09-02
SMAP200900041A (it) 2009-07-14
MX2009005360A (es) 2009-06-05
CO6382134A2 (es) 2012-02-15
GT200900133A (es) 2010-05-21
HRP20140627T1 (hr) 2014-09-26
CA2669199A1 (fr) 2008-05-29
US20100168153A1 (en) 2010-07-01
IL198467A0 (en) 2010-02-17
JP2013173788A (ja) 2013-09-05
ECSP099340A (es) 2009-06-30
PE20120083A1 (es) 2012-03-01
CN102336752A (zh) 2012-02-01
CN109970735A (zh) 2019-07-05
IL198467A (en) 2014-11-30
KR20140091718A (ko) 2014-07-22
UY30728A1 (es) 2008-07-03
JP5562033B2 (ja) 2014-07-30
NZ576357A (en) 2011-01-28
EA200900638A1 (ru) 2009-12-30
WO2008064093A3 (fr) 2008-08-14
AR064256A1 (es) 2009-03-25
CR10757A (es) 2009-06-11
JO2903B1 (en) 2015-09-15
WO2008064093A2 (fr) 2008-05-29
GEP20125436B (en) 2012-03-26
AU2007323820B2 (en) 2012-02-23
US20130289064A1 (en) 2013-10-31
JP2010510240A (ja) 2010-04-02

Similar Documents

Publication Publication Date Title
MA30967B1 (fr) Sels et formes cristallines de 2-methyl-2-methyl-2-[4-(3-methyl-2-oxo-8-quinolein-3-yl-2,3-dihydro-imidazo[4,5-c]quinolein-1-yl) - phenyl]-propionitrile.
MA32230B1 (fr) Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
EA201101243A1 (ru) 3h-имидазо[4,5-c]пиридин-6-карбоксамиды в качестве противовоспалительных средств
MA33332B1 (fr) Dérivés de la 1h-imidazo[4,5-c]quinolinone
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
DOP2008000001A (es) Oxazolidinonas substituidas y su uso
WO2005032471A3 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
GEP20105025B (en) Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases
WO2005004802A3 (fr) Inhibiteurs de la beta-secretase a base de n-alkyle phenylcarboxamide pour le traitement de la maladie d'alzheimer
EP2210092A4 (fr) Compositions comprenant des sémaphorines pour le traitement de maladies associées à l'angiogenèse et leurs procédés de sélection
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
WO2005051914A8 (fr) Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer
EP2651439A4 (fr) Compositions et procédés pour le traitement ou la prévention d'une infection par l'adénovirus 36 humain
ATE453646T1 (de) 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren
MA46268A (fr) Dérivés de 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
EP1749532A4 (fr) Médicament pour la guérison ou le traitement d'une blessure
MA29950B1 (fr) Nouveau derive de la pleuromutiline et son utilisation
EP2005194A4 (fr) Procédés utilisant de l'hémoglobine pour la prophylaxie, le diagnostic et/ou le traitement de troubles de la rétine
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EP2073635A4 (fr) Inhibiteurs de spiropipéridine macrocyclique de bêta-secrétase pour le traitement de la maladie d'alzheimer
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine